Compare AbbVie Inc (ABBV) vs Upwork Inc (UPWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Upwork Inc — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while Upwork Inc trades at $8.58 (market cap $1.10B). The key difference: AbbVie Inc is far larger — about 409× Upwork Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| ABBV | UPWK | |
|---|---|---|
Market Cap | $449.91B | $1.10B |
Sector | Health | Industrials |
52-Week High | $261.07 | $22.11 |
52-Week Low | $184.85 | $7.84 |
Enterprise Value | $513.38B | $895.35M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
UPWK trades at $8.87, down 3.17% today, with a bullish technical signal from moving averages and ADX indicators. The company reported $787.78M revenue in 2025 with a net income margin of 14.65%, though recent quarters show earnings misses. Positive developments include a new AI partnership with Claude announced June 17, 2026, while legal investigations into securities violations pose headwinds.
The stock presents a mixed outlook: valuation ratios like P/E of 10.94 and EV/EBITDA of 5.8 suggest potential upside to the $10.67 consensus target, but earnings volatility and legal risks require caution. Growth in the gig economy supports long-term opportunity, yet investor sentiment is tempered by recent guidance cuts and shareholder lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
